FluidFM nano-injection overcomes delivery limitations of current CRISPR gene editing methods, accelerates cell line development cycles, and is poised to significantly broaden multiplexing capabilities
Paul Monnier2, Jennifer Rottenberger1, Maria Milla2, Tobias Beyer2, Dario Ossola2, Justin S Antony1 and Markus Mezger1
1) University Children's Hospital, Department of Pediatrics I, Hematology and Oncology, University of Tübingen, Tübingen, Germany
2) Cytosurge AG, Saegereistrasse 25, 8152 Glattbrugg, Switzerland
Pharmaceutical and biological research as well as biologics manufacturing rely on genetically modified cell lines with genes that have been modified to induce the desired phenotype. With the discovery and development of gene editing technologies like CRISPR, the potential of doing multi-loci edits has received much interest but has proven to be a tedious and long process. Here we demonstrate the generation of a monoclonal multiple Knock-Out cell line in less than three weeks with the help of the FluidFM technology.